Inspection Record

Coastal Meds, LLC. — FDA 483 Findings

US FDAInspected 2015-11-07Published 2024-01-17 8 findingsTraining and personnelStability and storageRegulatory reporting and change controlAseptic processing and sterility assuranceComplaint and recall handlingLabeling and packaging

Inspectors Claire M. MindenThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform.

2Stability and storage

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

3Regulatory reporting and change control

Your outsourcing facility has not submitted product reports to FDA as required by section 503B(b)(2)(A).

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

5Complaint and recall handling

Complaint procedures are deficient in that they do not include provisions that allow for the review to determine if the complaints represent serious and unexpected adverse drug experiences which are required to be reported to FDA.

6Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions .

7Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

8Labeling and packaging

The labels of some of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A)and (B).

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Coastal Meds, LLC. findings history — including this company's other documents US FDA documents, 2024 Go to Findings search